Loading clinical trials...
Loading clinical trials...
Phase 1b & 2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (VIRO-15)
Conditions
Interventions
GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab
Locations
2
United States
Gynecologic Oncology Associates
Newport Beach, California, United States
AdventHealth Cancer Institute
Orlando, Florida, United States
Start Date
May 1, 2016
Primary Completion Date
December 31, 2021
Completion Date
December 31, 2022
Last Updated
January 5, 2023
NCT03050268
NCT06257264
NCT06964009
NCT00539162
NCT06915025
NCT06710548
Lead Sponsor
Genelux Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions